Do you think that your recommendations to the FDA are sufficient to mitigate this problem?
Paul Gosar
The Public Record
Paul Anthony Gosar is an American politician and dentist serving as the U.S. Representative for Arizona's 4th congressional district since 2013. A member of the Republican Party, Gosar has been involved in various legislative efforts and has taken positions on issues such as wildlife management and economic policies affecting rural communities. He has been a vocal advocate for his constituents, often addressing concerns related to agriculture and land use in Arizona. Gosar has also been known for his controversial statements and positions on various national issues.
Seems to me like what we're doing here, is we're--we have a disease here, and what we're doing with this report is we're treating the symptoms but we're not treating the disease.
I do not think that what you have put out here in your outlines are suitable for reform.
I don't think that the--the hypothesis or the conclusions you've come to are real.
This is critical mass. It's not just with pharmaceuticals but also our medical devices.
I find that disdainful. This is an instant turnaround of quickly $80 million. And we shouldn't be building unless we actually know what we have as an inventory and make sure that we're selling it.





